Potential of an anti-bevacizumab idiotype scFv DNA-based immunization to elicit VEGF-binding antibody response

Author(s)

Silva, Tabata Almeida ; Aguiar, Rodrigo Barbosa ; Mori, Marcelo ; Machado, Gabriel Esquitini ; Hamaguchi, Barbara ; Machado, Marcelo Ferreira Marcondes ; Moraes, Jane Zveiter

• Document type: Journal article
• Source: Gene Therapy; v. N/A, p. 5-pg., 2022-12-08.

Abstract

Anti-idiotype antibodies have been considered for vaccination approaches against different diseases, including cancers. Based on that, we previously described an anti-bevacizumab idiotype monoclonal antibody, 10.D7, that revealed detectable antitumor effects on a vascular endothelial growth factor (VEGF)-dependent tumor model. Herein, we evaluated the possible applicability of a single-chain variable fragment (scFv) for the 10.D7 antibody in a gene immunization strategy. After checking that mammalian cells transfected to express the 10.D7 scFv are recognized by bevacizumab, it was explored the ability of our scFv construction, in a gene-based scheme, to elicit an immune response containing VEGF-binding antibodies. The results provide evidence that the designed 10.D7 scFv construct maintains the anti-bevacizumab idiotype features and has potential to activate an immune response recognizing VEGF. (AU)

• FAPESP's process: 16/14358-2 - Study of the effect of anti-Id antibody 10.D7 in inhibiting metastasis and construction of genetic vaccine, scFv 10.D7, which mimics growth factor vascular endothelium (VEGF)
• Grantee: Jane Zveiter de Moraes
• Support Opportunities: Regular Research Grants